The best cancer treatment centers are not always right around the corner. Sometimes, it's necessary to travel far and wide to reach facilities offering the latest and greatest in cancer therapy. And when a back-and-forth commute is not possible due to daily or long-term treatment protocols, lodging becomes a necessity. And often, a hassle.

If you find yourself confronted with a stressful travel scenario, key into Joe's House. It's sure to ease your burden.

Think about this:

Joe's House is a non-profit organization that serves hospital staff and cancer patients in search of lodging. Founded in 2003 by Ann Calahan who for six years struggled to find appropriate accommodations during her late husband's cancer battle, Joe's House makes life a little easier for those fighting cancer on the road.

Joe's House features a centralized listing of lodging information for patients to access online or with a simple phone call (877-563-7468). For online searches, a drop-down menu allows patients, loved ones, and caregivers to locate lodging by selecting states, cities, and treatment facilities. Details on each lodging facility are available with information on amenities, rates, and reservation methods, and requirements.

I just gave this system a whirl. I chose Florida as my state, Gainesville as my city, and the hospital where I receive my treatment. Up popped four lodging locations -- two are free for cancer patients, one runs $10 per night, and the other charges $77 per night. Fortunately, I live right around the corner from my treatment center. But for those who don't, this service -- it's free -- is definitely worth trying.

Fewer women are getting mammograms. Facilities offering mammograms are closing. Mammogram machine usage is declining. And we don't really know why.

"We're heading in the wrong direction," says Carol Lee, professor of radiology at Yale University School of Medicine and chair of the American College of Radiology's commission on breast imaging.

"If this decline holds up, it will be very worrisome," she says.

"We're looking at a possible increase in deaths if we see this continue," according to Diana Balma, vice president of public policy at Susan G. Komen for the Cure.

Studies don't show which women -- rich or poor, young or old, educated or uneducated -- are skipping these critical screenings, but there are a few possible reasons for this dangerous drop.

Think about this:

Perhaps there are fewer facilities, staffed by fewer radiologists and technologists due to high lawsuit rates and modest reimbursement. This is scary -- because the number of women old enough to get screened is increasing.

Women may be missing out on all sorts of necessary medical care because of inadequate health insurance or other access problems.

Women may be choosing, for whatever reasons, not to get mammograms, despite strong public urging that women age 40 and older get screened one time every year.

And now think about this:

Recent news about declining breast cancer rates may not be all that good. It may not be that fewer women are developing breast cancer. It may simply be that fewer women are getting early diagnoses because of irregular or nonexistent screening.

The world's largest drug maker -- Pfizer Inc. -- announced Monday it will cut 10,000 jobs and close at least five facilities due to fierce competition from generic drug makers. The goal, says Pfizer spokespeople, is to whittle away annual costs by $2 billion by the end of the year -- to combat the prediction that the company will lose 41 percent of its sales to generic drugs between 2010 and 2012.

Pfizer's other obstacles include expiring drug patents -- costing Pfizer about $14 billion in revenues between 2005 and 2007 -- as well as demands for lower prices by insurers and large purchasers, and repeated requests for evidence of products' worth.

The 10,000 layoffs amount to 10 percent of the company's global workforce and will take jobs from 2,200 United States employees. The company will cut 20 percent of its European sales force, will close three research sites in Michigan and two manufacturing plants in New York and Nebraska, and is considering selling a manufacturing site in Germany and closing two research sites in Japan and France. In the midst of all of this, the company will focus its efforts on transforming the way they do business.

"I believe we must transform the way we've done business in the past in order to be more successful in the future," said Jeffrey Kindler, CEO and chairman of Pfizer. " Incremental evolution is not enough. Fundamental change is imperative -- and it must happen now."

Pfizer's Monday announcement is the second declaration of budget cuts. A previous announcement has the company -- the maker of cancer drugs Aromasin, Ellence, Camptosar, and Sutent -- slashing costs by $4 billion a year until 2008.